- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07704476
EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
14. juli 2026 opdateret af: Colin Champ, MD, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
EXERT-BC Protein: Randomized Study of Protein Supplementation to Improve Body Composition Improvement During Hypertrophy Exercise After Treatment for Breast Cancer
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
40
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Clinical Trials Contact
- Telefonnummer: 412-330-6151
- E-mail: ctgov@ahn.org
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15212
- AHN Allegheny General Hospital
-
Kontakt:
- Clinical Trials Contact
- Telefonnummer: 412-330-6151
- E-mail: ctgov@ahn.org
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance by a CSCS
- Must be able to read and understand English and consent for themselves.
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Beta blocker or GLP-1 inhibitor medications
- Pregnant women
- Males
- Lactose intolerance
- Cow's milk or whey protein allergy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: 60 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein.
The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened.
This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate.
Utilizing both will allow individuals with any sensitivity to have increased options.
The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage.
The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle).
|
60 grams of whey protein
|
|
Eksperimentel: 0 grams of protein
Participants will be randomized to a post-workout protein consisting of either no protein or 60 g of whey protein.
The protein is 100% cold processed and micro-filtered, non-GMO grass-fed whey protein isolate, soy and gluten free, unflavored, and unsweetened.
This will include Irish Dairy (AGN Roots, Ireland), which is whey protein isolate and soy lecithin, and Raw GrassFed Whey, which is whey protein concentrate.
Utilizing both will allow individuals with any sensitivity to have increased options.
The powder will be weighed by EOC staff in a private room prior to mixing with 12 oz of filtered water to ensure adequate dosage.
The protein will be mixed via a protein shaker bottle made of stainless steel (Bolde Bottle).
|
0 grams of whey protein
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Determine changes in pounds of muscle and fat mass after each exercise regimen
Tidsramme: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Determine changes in resting metabolic rate in calories per day at the completion of the exercise regimen
Tidsramme: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in body composition at the completion of the exercise regimen, including body mass in pounds, fat mass in pounds, fat-free mass in pounds, % fat, and % fat-free mass
Tidsramme: Baseline and at program completion (within 4 weeks of exercise completion)
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
|
Determine changes in Y-balance score at the completion of the exercise regimen
Tidsramme: Baseline and at program completion (within 4 weeks of exercise completion)
|
Y-Balance score measures the length an individual can extend their foot.
The larger the score the better the balance.
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Functional Movement Screen (FMS) scores at the completion of the exercise regimen
Tidsramme: Baseline and at program completion (within 4 weeks of exercise completion)
|
FMS measures movement patterns with scoring from 0 to 21.
The large the score the better the mobility.
|
Baseline and at program completion (within 4 weeks of exercise completion)
|
|
Determine changes in phase angle at the completion of the exercise regimen
Tidsramme: At program completion (at 8 weeks)
|
Phase angle measures the fluidity of cells and the larger the value the better.
|
At program completion (at 8 weeks)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Colin Champ, MD, CSCS, AHN Radiation Oncology
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. juni 2026
Primær færdiggørelse (Anslået)
1. marts 2027
Studieafslutning (Anslået)
1. juni 2027
Datoer for studieregistrering
Først indsendt
7. juli 2026
Først indsendt, der opfyldte QC-kriterier
14. juli 2026
Først opslået (Faktiske)
15. juli 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
15. juli 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. juli 2026
Sidst verificeret
1. juli 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Hudsygdomme
- Brystsygdomme
- Opførsel
- Hud- og bindevævssygdomme
- Neoplasmer
- Brystneoplasmer
- Motorisk aktivitet
- Aminosyrer, peptider og proteiner
- Proteiner
- Mad
- Diæt, mad og ernæring
- Fysiologiske fænomener
- Mad og drikkevarer
- Mejeriprodukter
- Mælk
- Diætproteiner
- Mælkeproteiner
- Animalproteiner, kost
- Valle
- Valleproteiner
Andre undersøgelses-id-numre
- 2026-159-SG
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Whey protein (60 grams)
-
University of California, DavisRekruttering
-
United States Army Research Institute of Environmental...RekrutteringMuskelmisbrug | Muskelafbrydelse atrofiForenede Stater
-
Maastricht University Medical CenterAfsluttetMuskelproteinsynteseHolland
-
The George Institute for Global Health, ChinaNingxia Medical UniversityAfsluttetHjerte-kar-sygdomme | DyslipidæmiKina
-
University of ArkansasNational Dairy CouncilRekrutteringPrædiabetes / Type 2-diabetesForenede Stater
-
Rabin Medical CenterBeit Rivka HospitalUkendt
-
VA Office of Research and DevelopmentAfsluttet
-
Société des Produits Nestlé (SPN)Afsluttet
-
VA Office of Research and DevelopmentAfsluttet
-
University of ExeterRekrutteringSunde deltagereDet Forenede Kongerige